Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK2586881 in Acute Lung Injury
NCT01597635Phase 2Completed
- Sponsor
- GSK
- Start
- Sep 2012
- Primary completion
- Oct 2014
- Modality
- Peptides, Replacement Enzymes
- Countries
- 2
01
Overview
A Phase 2 trial of alunacedase alfa in acute lung injury (ALI), acute respiratory distress syndrome (ARDS), sponsored by GSK. Started Sep 2012; status: completed.
02
Drugs
alunacedase alfa
03
Conditions
acute lung injury (ALI)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT01597635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01597635.